Jennifer Doudna

Co-founder, Mammoth Biosciences

Search every verified Jennifer Doudna interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Jennifer Doudna, co-founder of Scribe Therapeutics and a Nobel laureate, appeared on Bloomberg Technology on July 24, 2026, following Scribe Therapeutics' IPO, which raised $128.7 million. Doudna discussed the company's lead therapy, which aims to lower LDL cholesterol with a single treatment using "epi editing," a method she described as making changes in DNA that are not permanent but alter protein production. She stated that this approach could allow the therapy to be used "safely and effectively for common disease." Doudna also commented on the role of artificial intelligence in science, saying that while AI is "an incredible tool" that can accelerate work, it "doesn't replace scientists" and that she does not see AI coming up with "brand new idea[s]." In a June 24, 2026, interview on "The Circuit" with Emily Chang, Doudna reflected on the pace of CRISPR's commercialization, stating that the promise of the technology was not overstated but that "we're just early." She expressed a desire for a future where patients with rare diseases can be quickly diagnosed and receive a genetic therapy through a "smooth pipeline." Doudna also addressed the impact of funding cuts to scientific research, calling them a risk to the United States' economic success in science and technology.